Argá Medtech

Executive Summary

Argá Medtech is a Swiss medical device company pioneering a next-generation, non-thermal cardiac ablation system for the treatment of atrial fibrillation (AFib) and other arrhythmias. Founded in 2019 and based in Lausanne, the company's core innovation is a proprietary pulsed field ablation (PFA) system that utilizes a novel sine wave energy delivery technology. This approach aims to improve upon existing thermal ablation methods by reducing collateral tissue damage, shortening procedure times, and potentially enhancing patient outcomes. AFib is a growing global epidemic, affecting millions, and the market for ablation devices is expanding rapidly, with PFA emerging as a disruptive technology. Argá's differentiated sine wave PFA platform positions it to capture significant share in this competitive landscape. The company is currently in the preclinical and early clinical development phase, with a focus on validating the safety and efficacy of its system. Argá's team combines deep expertise in electrophysiology and medical device innovation. Given the strong interest in PFA from major players and clinicians, successful clinical data and regulatory clearances could unlock substantial value. The company operates with a lean structure typical of early-stage medtech, and its Swiss base offers access to top-tier research and manufacturing capabilities. Argá Medtech represents a promising investment opportunity in the cardiac ablation space, contingent on achieving key technical and regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial results60% success
• Q2 2027CE mark submission for PFA system70% success
• Q1 2027Series B funding round or strategic partnership75% success